EFFECT OF RIFAMPICIN PRETREATMENT ON HIPOGLYCEMIC EFFECT OF GLYPIZIDE AMONG HEALTHY VOLUNTEERS

Luciana Kuswibawati

Abstract


The incidence of tuberculosis in diabetic patients is high, therefore, the combination usage of antituberculosis (rifampicin) and antidiabetic (glypizide) medicines is inevitable. Rifampicin, an enzyme inductor, capable to influence the metabolism of other medicine when administered in concordance. The aimed of this study, therefore, was to investigate the influence of rifampicin pre-treatment on hypoglycaemic effect of glypizide (a second generation of sulphonylurea) among 12 Indonesia healthy volunteers, of both sexes. This study applied randomized crossover design receiving with and without rifampicin pre-treatment. Prior to starting the experiment, the pre-treatment group was given 450 mg of rifampicin orally daily for 7 days. Subsequently, single dose of 5 mg glypizide was administered to both of control and pre-treatment groups. The blood samples were then collected at a certain interval time for 7 hours. Glucose Oxydase (GOD) method were used to analyze the level of glucose in blood samples. The result showed no significant influence of rifampicin on hypoglycaemic effect of glypizide. However, it was found that rifampicin reduced significantly blood glucose level at 2.5 and 3 hours for 51.38 % and 20.58 %, respectively. The conclution of this study exhibit that pre-treatment with 450 mg of rifampicin daily for 7 days did not affect AUC0-7 blood glucose level as a result of single dose administration of 5 mg glypizide.

Key words : rifampicin, glypizide, hypoglycaemic effect


Full Text:

Untitled

References


Anonim, 2000, Guidance for industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Prodructs.

Asdie, A.H., 2000, Patogenesis dan Terapi Diabetes Mellitus tipe 2, Medika Fakultas Kedokteran, Universitas Gadjah Mada, Yogyakarta.

Backman, J.T., Olkkala, K.T. & Neuvonen, P.J. 1996, Rifampicin drastically reduces plasma concentrations and effects of oral midazolam, Clin. Pharmacol. The.r; 59:7-13.

Budiarto, L. dan Hisyam, B., 2001, Beberapa aspek klinik tuberkulosis paru dengan diabetes mellitus, Lab/UPF Penyakit Dalam FK-UGM/RSUP DR. Sardjito, Yogyakarta.

Dolleri, C., 1992, Therapeutic Drugs, vol 1 & 2, Churchill Livingstone Medical Division of Longman Group UK, Edinburg.

Fordiastiko, 1995, Penatalaksanaan tuberkulosis paru pada penderita diabetes mellitus, Paru, 15(3): 105-110.

Hamman, M.A., Bruce, M.A., Hachner-Daniels, B.D., Hall, S.D., 2001, The effect of rifampicin administration on the disposition of fexofenadine, Clin. Pharmacol. Ther.; 69:114-121.

Hamzah, G., Bardiman, S., & Halim, H., 1993, Insiden penderita tuberkulosis paru dengan diabetes mellitus yang dirawat di Lab/UPF Penyakit Dalam FK UNSRI RSUP Palembang (1988-1992) in Acta Medica Indonesiana, XXI:2 Maret-Juni 1993, Kongres Persatuan Penyakit Dalam Indonesia IX, Denpasar.

Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J., Kivisto,K.T., 2000, Rifampicin decreases the plasma concentrations and effects of repaglinide, Clin. Pharmacol. Ther.; 68:495-500.

Niemi, M., Backman, J.T., Olkkala, K.T., Neuvonen, M., Neuvonen, P.J., Kivisto,K.T., 2001, Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizid, Clin. Pharmacol.Ther.; 69:400-406.

Patau, Y., Abdullah, A., Adam, J.M.F., & Djunaedi, 1989, Beberapa aspek klinik tuberkulosis paru pada penderita diabetes mellitus in Kumpulan Makalah Kopapdi VIII Yogyakarta jilid III, Persatuan Ahli Penyakit Dalam Indonesia cabang Yogyakarta.

Pozzilli, P., Signore, A., Leslie, R.D.G., 1997, Infection, immunity and diabetes in. K.G.M.M Alberti, R.A.P. Zimmet DeFonzo: International Texbook of Diabetes Mellitus, pp.1231-1241, John Wiley & Sons Ltd.Toronto.

Stumvoll, M., Mitrakou, A., Pimenta, W., Jenssen, T., Yki-jarvinen, H., Van Haeften, T., Renn, W., Gerich, J., 2000, Use of the oral glucose tolerance test to asses insulin release and insulin sensitivity, Diabetes Care 23:295-301.

Villikka, K., Kivisto, K.T., Luurila, H. & Neuvonen, P.J., 1997, Rifampicin reduces plasma concentrations and effects of zolpidem, Clin. Pharmacol. Ther.; 62: 629-634.

Villikka, K., Kivisto, K.T. & Neuvonen, P.J., 1999, The effects of rifampicin on the pharmacokinetics of oral and intravenous ondansetron, Clin. Pharmacol. Ther.; 65: 377-381.

Yoesoef, H., Tanjung, R., Pelly, R., Aisyah, N., 1989, Tuberkulosa paru dengan diabetes mellitus di Laboratorium Ilmu Penyakit Dalam FK-USU RS.DR. Pirngadi Medan dalam Kumpulan Makalah

Kopapdi VIII Yogyakarta jilid III, Persatuan Ahli Penyakit Dalam Indonesia cabang Yogyakarta.




DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp299-305

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

web
analytics View My Stats